Table II.
Dispositions of patients enrolled to the TElmisartan plus AMlodipine STudy (TEAMSTA) Follow-Up studies.
| Visit | TEAMSTA-5 Follow-Up |
TEAMSTA-10 Follow-Up |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall⁎ | T40/A5⁎ | Uptitrated to T80/A5 | Uptitrated to T80/A5 + add-on | T40/A5 + add-on | Overall† | T40/A10† | T40/A10 + add-on | T80/A10 | T80/A10 + add-on | |
| ← - - - - - - - - - - - - - - n (%) - - - - - - - - - - - - - - → | ||||||||||
| 1 (week 0) | 976 (100) | 976 (100) | 0 | 0 | 0 | 838 (100) | 838 (100) | 0 | 0 | 0 |
| 2 (week 4) | 959 (100) | 959 (100) | 0 | 0 | 0 | 831 (100) | 831 (100) | 0 | 0 | 0 |
| 3 (week 8) | 952 (100) | 738 (67.0) | 313 (32.9) | 0 | 1 (0.1) | 822 (100) | 336 (40.9) | 0 | 486 (50.1) | 0 |
| 4 (week 14) | 949 (100) | 575 (60.5) | 257 (27.1) | 116 (12.2) | 1 (0.1) | 818 (100) | 217 (26.5) | 3 (0.4) | 554 (67.7) | 44 (5.4) |
| 5 (week 22) | 939 (100) | 550 (58.6) | 210 (22.4) | 164 (17.5) | 15 (1.5) | 811 (100) | 208 (25.6) | 8 (1.0) | 518 (63.9) | 77 (9.5) |
| End of study | 976 (100) | 564 (57.6) | 206 (21.1) | 181 (18.5) | 25 (2.6) | 838 (100) | 219 (26.1) | 8 (1.0) | 527 (62.9) | 84 (10.0) |
Add-on = additional antihypertensive medication; T40/A5 = telmisartan 40 mg plus amlodipine 5 mg; T80/A5 = telmisartan 80 mg plus amlodipine 5 mg; T40/A10 = telmisartan 40 mg plus amlodipine 10 mg; T80/A10 = telmisartan 80 mg plus amlodipine 10 mg.
At each visit, the number of patients is reflecting the treatment that the patient was allocated to at the preceding visit. Eleven patients were excluded from the efficacy analysis due to no blood pressure measurement at Visits 2–5 or end of study.
At each visit, the number of patients is reflecting the treatment that the patient was allocated to at the preceding visit. Three patients were excluded from the efficacy analysis due to no blood pressure measurement at Visits 2–5 or end of study.